STAT Plus: Data on Amgen’s KRAS-blocking cancer drug are encouraging, but also raise new questions
Last June, Amgen excited cancer scientists and investors alike with the first tumor-shrinking results from a medicine targeted against the “undruggable” KRAS protein.
On Sunday, the biotech presented another round of data on the KRAS-blocking drug called AMG 510. Like this past summer, tumor responses hover around 50% — more impressive now because the analysis comprises a larger number of lung cancer patients. But the details also reveal some questions about AMG 510 that will require further time and study to answer.
Continue to STAT Plus to read the full story…
